Towards selective lysophospholipid GPCR modulators

Trends in Pharmacological Sciences

Volumn 35, Issue 5, 2014, Pages 219-226

  Archbold, Julia K ^a   Martin, Jennifer L ^a   Sweet, Matthew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

endothelial derived growth factor (Edg); G protein coupled receptors (GPCRs); GPCR structure; lysophosphatidic acid (LPA); sphingosine 1 phosphate (S1P)

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ENDOTHELIAL-DERIVED GROWTH FACTOR (EDG); G-PROTEIN-COUPLED RECEPTORS (GPCRS); GPCR STRUCTURE; LYSOPHOSPHATIDIC ACID (LPA); SPHINGOSINE 1-PHOSPHATE (S1P);

BINDING SITES; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, MOLECULAR; RECEPTORS, LYSOPHOSPHOLIPID;

EID: 84899624599     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.03.004     Document Type: Review

References (72)

1. K. Yanagida et al. Current progress in non-Edg family LPA receptor research Biochim. Biophys. Acta 1831 2013 33 41
2. K. Yanagida, and S. Ishii Non-Edg family LPA receptors: the cutting edge of LPA research J. Biochem. 150 2011 223 232
3. J. Chun et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature Pharmacol. Rev. 62 2010 579 587
4. K. Makide, and J. Aoki GPR34 as a lysophosphatidylserine receptor J. Biochem. 153 2013 327 329
5. H.Y. Zhu, and W.M. Da Regulation of immunity by sphingosine 1-phosphate and its G protein-coupled receptors - review Zhongguo Shi Yan Xue Ye Xue Za Zhi 15 2007 1317 1324 (in Chinese)
6. J.W. Choi et al. LPA receptors: subtypes and biological actions Annu. Rev. Pharmacol. Toxicol. 50 2010 157 186
7. O. Dereure Involvement of receptor P2Y5 and its ligand LPA in hypotrichosis simplex and autosomal recessive wooly hair syndrome Ann. Dermatol. Venereol. 135 2008 794 795
8. K. Yanagida et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6 J. Biol. Chem. 284 2009 17731 17741
9. J.W. Choi, and J. Chun Lysophospholipids and their receptors in the central nervous system Biochim. Biophys. Acta 1831 2013 20 32
10. I. Ishii et al. Lysophospholipid receptors: signaling and biology Annu. Rev. Biochem. 73 2004 321 354
11. D.A. Lin, and J.A. Boyce Lysophospholipids as mediators of immunity Adv. Immunol. 89 2006 141 167
12. K. Noguchi, and J. Chun Roles for lysophospholipid S1P receptors in multiple sclerosis Crit. Rev. Biochem. Mol. Biol. 46 2011 2 10
13. W.J. Valentine et al. Lysophospholipid signaling: beyond the EDGs Biochim. Biophys. Acta 1780 2008 597 605
14. C.R. Strader et al. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite J. Nat. Prod. 74 2011 900 907
15. M.J. Lee et al. Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist J. Biol. Chem. 273 1998 22105 22112
16. W.J. Valentine et al. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors J. Biol. Chem. 283 2008 12175 12187
17. P. Brossard et al. Pharmacokinetics and pharmacodynamics of Ponesimod, a selective S1P receptor modulator, in the first-in-human study Br. J. Clin. Pharmacol. 76 2013 888 896
18. M.H. Bolli et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists J. Med. Chem. 53 2010 4198 4211
19. M.H. Bolli et al. Novel S1P1 receptor agonists - Part 1: from pyrazoles to thiophenes J. Med. Chem. 56 2013 9737 9755
20. G. Jiang et al. Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists Bioorg. Med. Chem. Lett. 23 2013 1865 1869
21. J.I. Fells et al. Identification of non-lipid LPA3 antagonists by virtual screening Bioorg. Med. Chem. 16 2008 6207 6217
22. G.N. Kiss et al. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions Mol. Pharmacol. 82 2012 1162 1173
23. M.A. Hanson et al. Crystal structure of a lipid G protein-coupled receptor Science 335 2012 851 855
24. V. Katritch et al. Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 53 2013 531 556
25. A.L. Parrill, and G. Tigyi Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions Biochim. Biophys. Acta 1831 2013 2 12
26. Y. Fujiwara et al. Identification of the hydrophobic ligand binding pocket of the S1P1 receptor J. Biol. Chem. 282 2007 2374 2385
27. T.C. Pham et al. Molecular recognition in the sphingosine 1-phosphate receptor family J. Mol. Graph. Model. 26 2008 1189 1201
28. P.B. van Loenen et al. Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor Eur. J. Pharmacol. 667 2011 105 112
29. A.L. Parrill Comparative modeling of lipid receptors Methods Mol. Biol. 914 2012 207 218
30. J. Carlsson et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure Nat. Chem. Biol. 7 2011 769 778
31. V.M. Sardar et al. Molecular basis for lysophosphatidic acid receptor antagonist selectivity Biochim. Biophys. Acta 1582 2002 309 317
32. Y. Fujiwara et al. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells J. Biol. Chem. 280 2005 35038 35050
33. Y. Inagaki et al. Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors Biochem. J. 389 2005 187 195
34. J.R. Williams et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation J. Biol. Chem. 284 2009 17304 17319
35. R. Nygaard et al. The dynamic process of beta(2)-adrenergic receptor activation Cell 152 2013 532 542
36. D.R. Weiss et al. Conformation guides molecular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor ACS Chem. Biol. 8 2013 1018 1026
37. M. Congreve et al. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design J. Med. Chem. 55 2012 1898 1903
38. C.J. Langmead et al. Identification of novel adenosine A(2A) receptor antagonists by virtual screening J. Med. Chem. 55 2012 1904 1909
39. H. Satsu et al. A sphingosine 1-phosphate receptor 2 selective allosteric agonist Bioorg. Med. Chem. 21 2013 5373 5382
40. E. Jo et al. Novel selective allosteric and bitopic ligands for the S1P(3) receptor ACS Chem. Biol. 7 2012 1975 1983
41. J.J. Liu et al. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR Science 335 2012 1106 1110
42. T. Warne et al. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol Structure 20 2012 841 849
43. C. Mpamhanga Lysophospholipid (LPA) receptors International Union of Basic and Clinical Pharmacology (IUPHAR) Database 2013 http://www.iuphar-db.org/ DATABASE/
44. L. Ma et al. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model Mol. Pain 9 2013 29
45. L. Ma et al. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain Mol. Pain 5 2009 64
46. S. Ishii et al. Non-Edg family lysophosphatidic acid (LPA) receptors Prostaglandins Other Lipid Mediat. 89 2009 57 65
47. S. Matayoshi et al. Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells Int. J. Oncol. 42 2013 1560 1568
48. M.E. Lin et al. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain J. Biol. Chem. 287 2012 17608 17617
49. S.M. Pasternack et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth Nat. Genet. 40 2008 329 334
50. J.E. Lattin et al. Expression analysis of G protein-coupled receptors in mouse macrophages Immunome Res. 4 2008 5
51. T. Hla, and V. Brinkmann Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation Neurology 76 2011 S3 S8
52. C. Mpamhanga Lysophospholipid (S1P) receptors International Union of Basic and Clinical Pharmacology (IUPHAR) Database 2013 http://www.iuphar-db.org/ DATABASE/
53. H. Rosen et al. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence Annu. Rev. Biochem. 82 2013 637 662
54. J.S. Swaney et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist J. Pharmacol. Exp. Ther. 336 2011 693 700
55. H. Ohta et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Mol. Pharmacol. 64 2003 994 1005
56. Y. Hasegawa et al. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor J. Biol. Chem. 278 2003 11962 11969
57. V. Gududuru et al. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors Bioorg. Med. Chem. Lett. 16 2006 451 456
58. T. Virag et al. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors Mol. Pharmacol. 63 2003 1032 1042
59. J.I. Fells et al. Structure-based drug design identifies novel LPA3 antagonists Bioorg. Med. Chem. 17 2009 7457 7464
60. A.L. Khandoga et al. Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin Platelets 19 2008 415 427
61. M. Urbano et al. Modulators of the sphingosine 1-phosphate receptor 1 Bioorg. Med. Chem. Lett. 23 2013 6377 6389
62. P.J. Gonzalez-Cabrera et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions Mol. Pharmacol. 74 2008 1308 1318
63. T. Komiya et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis Clin. Exp. Immunol. 171 2013 54 62
64. L. Piali et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation J. Pharmacol. Exp. Ther. 337 2011 547 556
65. M.G. Sanna et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate J. Biol. Chem. 279 2004 13839 13848
66. J.J. Clemens et al. Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists Bioorg. Med. Chem. Lett. 13 2003 3401 3404
67. J. Song et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice J. Pharmacol. Exp. Ther. 324 2008 276 283
68. M.D. Davis et al. Sphingosine 1-phosphate analogs as receptor antagonists J. Biol. Chem. 280 2005 9833 9841
69. F.W. Foss Jr et al. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists Bioorg. Med. Chem. 15 2007 663 677
70. T. Sanchez, and T. Hla Structural and functional characteristics of S1P receptors J. Cell. Biochem. 92 2004 913 922
71. M. Guerrero et al. Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists Bioorg. Med. Chem. Lett. 21 2011 3632 3636
72. M. Guerrero et al. Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists Bioorg. Med. Chem. Lett. 22 2012 537 542